Tyrian Strengthens Board With New Appointment

  
    
  
  
    
      Tyrian Diagnostics Limited (ASX:TDX) announced today the 
      appointment of new board member, Dr Merilyn Sleigh and the resignation 
      of John Martin.
    
    
      Dr. Sleigh joins Tyrian with a background in biological research with 
      CSIRO and is currently a non-executive director of Clover Corporation, 
      Mimetica Pty Ltd and the Rural Industries Research and Development 
      Council. She is also a member of the Federal Government’s Task Force 
      developing a 10 year strategy for the pharmaceutical industry in 
      Australia, and advises CSIRO and the Garvan Institute for Medical 
      Research on research commercialisation. Previously, she was the Managing 
      Director of the antibody therapeutics company EvoGenix Ltd.
    
    
      “The Board is delighted that Merilyn will join us as a non-executive 
      director,” said Roger Amos, Chairman of Tyrian. “She has an impressive 
      track record in the Australian biotech sector and we’re pleased she can 
      bring her corporate growth experience to Tyrian. The appointment of 
      Merilyn together with the recent appointment of Dr Caroline Popper means 
      the Board is now well structured to oversee the Company’s next growth 
      phase in building its diagnostic product pipeline”.
    
    
      TDX also announced the resignation of John Martin from its Board. John 
      has been a director since 2000 and a non-executive director since his 
      departure as Deputy CEO in 2004 to accept a position with Babcock & 
      Brown to build its retirement & aged care platform, resulting in his 
      appointment as Managing Director of B & B Communities. Since then, John 
      has made a valuable contribution in assisting the Board to successfully 
      reposition the Company to take full advantage of its core capabilities. 
      Roger Amos said “I have appreciated John’s unique contribution over the 
      past 18 months or so we have worked together. As the longest serving 
      director he brought considerable insight to the issues the Board has 
      faced in refocusing the Company’s activities.”
    
    
      About Tyrian Diagnostics
    
    
      Tyrian Diagnostics (ASX: TDX) is a diagnostics company with expertise in 
      biomarker discovery and validation and diagnostic test development and a 
      core focus on respiratory and infectious diseases. In addition, Tyrian 
      can partner in alternative fields given its capabilities to work across 
      the entire spectrum of diagnostic test development – from identification 
      and isolation of biomarkers, point-of-need test design, clinical 
      development or field testing to final product. Tyrian’s product pipeline 
      includes: WheatRite® for measuring wheat quality, which is partnered 
      with BayerCropSciences; and a rapid test for active tuberculosis, in 
      collaboration with Becton Dickinson and Company.
    
    
      Additional information about Tyrian Diagnostics can be found at www.tyriandx.com